Sangamo Therapeutics reports fourth quarter and full year 2017 financial results
Sangamo reported the consolidated net loss was $54.6 million, or $0.70 per share in FY 2017, versus a consolidated net loss of $71.7 million, or $1.02 per share, in 2016. Revenues were $36.6 million for the 2017 year end versus $19.4 million in 2016. February 22, 2018